An ASCOT analysis finds high blood pressure variability is strongly linked to worse cardiovascular and renal outcomes in diabetes, with amlodipine-based therapy reducing events partly via lower variability. PICO summary and commentary.
Browsing: Heart Failure & Renal Protection
Summary: In adults with HFpEF (EF ≥50%), obesity (BMI ≥30 kg/m²), stratified by presence or absence of type 2 diabetes…
A prespecified SUMMIT analysis finds tirzepatide reduces heart-failure events in obese HFpEF regardless of diabetes status, despite less weight loss with diabetes. PICO summary and commentary.
A DAPA-MI subanalysis finds dapagliflozin reduces new-onset diabetes after heart attack regardless of glucose or BMI, with most symptom benefit in prediabetes. PICO summary and commentary.
A randomised trial finds dapagliflozin reduces myocardial fibrosis and improves cardiac structure in diabetic HFpEF. PICO summary and expert commentary.
A small acute mechanistic crossover study testing whether exenatide-glucagon co-infusion raises myocardial glucose uptake and a diastolic strain-rate marker in eight adults with type 2 diabetes. PICO summary and expert commentary.
A secondary analysis of the VA NEPHRON-D cohort found that higher baseline urinary EGF and uromodulin were independently associated with a lower risk of diabetic kidney disease progression. PICO summary and expert commentary.
A randomized crossover trial found the cardiac output response to 3-hydroxybutyrate was blunted by roughly 80% in type 1 diabetes, with no gain in systolic function and reduced ventricular work efficiency. PICO summary and expert commentary.
A post-hoc EXSCEL analysis testing whether baseline ejection fraction modifies the effect of once-weekly exenatide on heart failure hospitalisation in type 2 diabetes. PICO summary and expert commentary.
In the SOGALDI-PEF crossover trial, adding spironolactone to dapagliflozin produced a modest 11% NT-proBNP reduction in HFmrEF/HFpEF, offset by eGFR decline and higher potassium. PICO summary and expert commentary.